hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06379802 id: 2023-00546-01 briefTitle: Lifestyle Intervention With Physical Activity and Diet acronym: LI-PAD overallStatus: RECRUITING date: 2024-02-12 date: 2025-12-31 date: 2027-12-31 date: 2024-04-23 date: 2024-04-23 name: Vastra Gotaland Region class: OTHER_GOV briefSummary: The aim of this pilot randomized controlled trial LI-PAD is to identify whether a 6-month intervention approach to individually optimize lifestyle behavior, physical activity, and diet, is feasible and leads to larger improvements in body weight, cardiovascular disease risk factors, and health-related quality of life compared to simple written lifestyle advice, in individuals with overweight or obesity.
nctId: NCT06379789 id: R131L1265-HEMB-2318 id: 2023-507260-40-00 type: REGISTRY domain: EU CTR Number briefTitle: A Trial to Learn if REGV131-LNP1265 is Safe and Works to Help the Body Make Clotting Factor in Pediatric, Adolescent and Adult Patients With Hemophilia B acronym: BEYOND-9 overallStatus: NOT_YET_RECRUITING date: 2024-07-25 date: 2032-07-03 date: 2032-07-03 date: 2024-04-23 date: 2024-04-23 name: Regeneron Pharmaceuticals class: INDUSTRY name: Intellia Therapeutics briefSummary: Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the "study drug". Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy.
* Whether there is a difference in 2 different methods for measuring Factor 9 activity in the blood conditions: Hemophilia B studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 130 type: ESTIMATED name: REGV131 name: LNP1265 measure: Incidence of treatment-emergent adverse events (TEAEs) measure: Severity of TEAEs measure: Coagulation Factor IX (FIX) functional activity measured using the chromogenic substrate assay measure: Change in FIX functional activity in plasma, measured using the chromogenic substrate assay measure: Annualized bleeding rate (ABR) following sustained FIX functional activity among participants receiving the RDE measure: Change in FIX functional activity in plasma measured using the chromogenic substrate assay measure: ABR following sustained FIX functional activity among participants receiving the RDE measure: FIX functional activity in plasma over time during the study period using the chromogenic substrate assay measure: Annualized treated bleeding rate (tABR) following sustained FIX functional activity, among participants receiving the RDE measure: Annualized utilization (IU/kg/year) of FIX replacement therapy following sustained FIX functional activity among participants receiving the RDE measure: Remaining free of FIX replacement therapy among those receiving the RDE following sustained FIX expression measure: Remaining zero spontaneous bleeding events among those receiving the RDE over sustained FIX functional activity period measure: Concentrations of REGV131 components measure: Concentrations of LNP1265 components measure: Detection of antibodies to the F9 transgene product FIX protein measure: Detection of total binding antibodies (TAbs) to the adeno-associated virus 8 (AAV8) capsid proteins measure: Detection of neutralizing antibodies/transduction inhibitors (NAb/TI) to the adeno-associated virus 8 (AAV8) capsid proteins measure: Detection of antibodies to LNP1265 measure: Detection of antibodies to CRISPR-associated protein 9 (Cas9) protein measure: Detection of vector DNA in blood measure: Detection of vector DNA in saliva measure: Detection of vector DNA in nasal secretions measure: Detection of vector DNA in semen measure: Detection of vector DNA in urine measure: Detection of vector DNA in feces measure: Incidence of TEAEs measure: Severity of TEAEs measure: Detection of vector DNA in relevant matrices based on data analysis of Part 1 Dose Confirmation Cohort measure: Detection of vector DNA in relevant matrices over time based on data analysis from adult cohorts over time sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06379776 id: LabForSIMS-LC1 briefTitle: 3D Model - Classification of Thoracic and Lumbar Spinal Fractures. overallStatus: NOT_YET_RECRUITING date: 2024-05-25 date: 2026-09-30 date: 2026-09-30 date: 2024-04-23 date: 2024-04-23 name: Université Paris-Sud class: OTHER briefSummary: The goal of this clinical trial is to evaluate and compare the effectiveness of a 3D interactive model versus traditional teaching methods in enhancing the teaching of thoracic and lumbar spine fractures classification (AO Spine) among orthopedic residents.
The study aims to ascertain if the use of the 3D model significantly enhances residents' comprehension of spine fractures compared to conventional teaching methods within the orthopedic curriculum. conditions: Lumbar Spine Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Education through a 3D model name: Education through a traditional pedagogical support measure: Specific Questionnaire measure: Objective Structured Assessment of Technical Skills (OSATS) measure: Subjective questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06379763 id: 170/2024 briefTitle: Effect of Diaphragmatic Breathing Exercise on Pain and Sleep Quality in Individuals With Non-specific Chronic Neck Pain overallStatus: RECRUITING date: 2024-03-01 date: 2024-05-30 date: 2024-06-30 date: 2024-04-23 date: 2024-04-23 name: University of Jordan class: OTHER briefSummary: This research focuses on adding diaphragmatic breathing to conventional physiotherapy sessions, particularly for patients suffering from chronic neck pain aged between 20-40 years in Jordan. Chronic neck pain is recognized as one of the most prevalent musculoskeletal pain disorders, significantly impacting physical, social, and psychological aspects of life. This issue leads to a decline in functional performance and work productivity, negatively affecting both individual and societal levels. Several factors, such as poor posture and prolonged use of smartphones, contribute to the exacerbation of non-specific chronic neck pain. These problems also affect respiratory muscles, particularly the diaphragm responsible for primary respiration, resulting in a shift from abdominal to chest breathing. This alteration increases the use of neck muscles, subsequently intensifying neck pain and negatively impacting sleep quality in these individuals. The primary objective of this therapeutic study is to investigate the role of adding diaphragmatic breathing to physiotherapy sessions in alleviating pain and improving sleep quality.
RCT study will investigate the effect of adding the diaphragmatic breathing to conventional physiotherapy treatment on pain and sleep quality over one month. conditions: Non-specific Chronic Neck Pain conditions: Diaphragmatic Breathing Exercise studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized clinical trial (RCT) Participants will be randomly allocated into two groups using the block randomization method. The following groups will be formed: experimental group A (diaphragmatic breathing plus conservative physiotherapy intervention, cervical neck ROM, neck stretching exercises), and group B, primaryPurpose: TREATMENT masking: SINGLE maskingDescription: the participants will not know which of exercises that will be giving for them more better in experimental or control group whoMasked: PARTICIPANT count: 40 type: ESTIMATED name: diaphragmatic breathing exercise name: conventional physiotherapy exercise measure: neck pain measure: neck pain measure: sleep quality sex: ALL minimumAge: 20 Years maximumAge: 40 Years stdAges: ADULT facility: The university of Jordan status: RECRUITING city: Amman zip: 11942 country: Jordan name: ISLAM ALNAQEEB, master role: CONTACT phone: 00962797246713 email: islam.alnaqeeb01@gmail.com name: Musab Abu beidar, master role: CONTACT phone: 00962790319243 email: musababubaider@gmail.com lat: 31.95522 lon: 35.94503 hasResults: False
nctId: NCT06379737 id: 359n/AO/23 id: MASI_CARIVARI21_01 type: OTHER_GRANT domain: Fondazione Cariparo briefTitle: Multi-systemic Rehabilitative Interventions in Long COVID-19 Patients in Two Different Settings: a Randomized Controlled Trial acronym: MULTI-COVID overallStatus: COMPLETED date: 2023-01-01 date: 2023-12-20 date: 2023-12-20 date: 2024-04-23 date: 2024-04-23 name: Padua University General Hospital class: OTHER briefSummary: Objective: This study aimed to evaluate the effectiveness of a multisystem rehabilitation program for Long Covid patients in two different settings.
Outcomes: Assessments were conducted before (T0) and after treatment (T1), at 3 (T2) and 6 months (T3), including respiratory and physical function, handgrip strength, fatigue, pain, quality of life, psychological function, and satisfaction. conditions: Long COVID studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 72 type: ACTUAL name: Multi-systemic Rehabilitation measure: Numerical Rating Scale (NRS) measure: Hand grip strength measure: Barthel Dyspnea Scale measure: Fatigue Assessment Scale measure: Beck's Depression Inventory (BDI measure: Beck Anxiety Inventory (BAI) measure: 12-Item Short Form Health Survey (SF-12) measure: Patients satisfaction sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Universityof Padua city: Padova zip: 35128 country: Italy lat: 45.40797 lon: 11.88586 hasResults: False
nctId: NCT06379724 id: 150349 briefTitle: Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-12 date: 2026-12 date: 2024-04-23 date: 2024-04-23 name: University of Kansas Medical Center class: OTHER briefSummary: Investigators hypothesize that topical tranexamic acid will have better or comparable efficacy to topical thrombin in reducing hematoma formation at the wound base. The purpose of the study is to demonstrate that topical tranexamic acid will be a non-inferior alternative medication to the current standard of care,THROMBIN-JMI® , and at a lower cost to the health system. conditions: Burns conditions: Skin Graft Complications studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective, randomized, blinded, non-inferiority study primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Subjects will be blinded to their randomization group. Study subject number will be linked to their randomization group. Blinding may be broken if the subject experiences an adverse reaction to the medication utilized for their group so that they are aware that they cannot receive the medication in the future. The research coordinator will have the code to the blind. The surgical team will not be blinded as the overall consistency of the topical agents will differ and may be apparent. whoMasked: PARTICIPANT count: 62 type: ESTIMATED name: Tranexamic acid name: Thrombin JMI name: skin graft measure: The number of participants with hematoma occurrence measure: The rate of percentage of graft take adherence amongst participants measure: Comparison of number of participants that require re-operation measure: Difference in cost between two hemostatic agents sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06379711 id: H22-03727 briefTitle: Cardiopulmonary Changes Following Spinal Cord Stimulation in Individuals With Spinal Cord Injury overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2028-08-01 date: 2028-08-01 date: 2024-04-23 date: 2024-04-23 name: University of British Columbia class: OTHER briefSummary: The aim of this study is to examine the mechanisms of transcutaneous spinal cord stimulation (tSCS) for improving cardiovascular and pulmonary function in individuals with chronic motor-complete spinal cord injury (SCI) by measuring vascular related endothelial biomarkers, plasma catecholamines, and respiratory parameters. conditions: Spinal Cord Injuries conditions: Cardiovascular Diseases conditions: Cardiopulmonary Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Pre-Post Study primaryPurpose: TREATMENT masking: NONE count: 22 type: ESTIMATED name: Transcutaneous Spinal Cord Stimulation (tSCS) measure: Circulating endothelial biomarkers in EMV/µL (Park et al., 2023) measure: Plasma catecholamines in nmol/L (Claydon & Krassioukov, 2008) measure: Spirometric parameters for lung volume in ml/kg (Aung et al., 2019) for FVC measure: Spirometric parameters for lung volume in ml/kg (Aung et al., 2019) for FEV1 sex: ALL minimumAge: 19 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Blusson Spinal Cord Centre city: Vancouver state: British Columbia zip: V5Z 1M9 country: Canada lat: 49.24966 lon: -123.11934 hasResults: False
nctId: NCT06379698 id: CHUBX 2023/78 briefTitle: Rein 3D PRINT PERSONALIZE acronym: R3DP-P overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2027-06-15 date: 2027-06-15 date: 2024-04-23 date: 2024-04-23 name: University Hospital, Bordeaux class: OTHER briefSummary: The goal of this clinical trial is to compare preoperative information and patient experience using a personalized versus a generic 3D printed models of patients' tumoral kidney before and after nephron-sparing surgery. The main outcome measure will be based on semi-structured interviews with the patient and the carers. conditions: Tumoral Kidney studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 90 type: ESTIMATED name: personalized 3D model pré-opérative education name: generic 3D model pré-opérative education measure: Qualitative assessment of patient experience 1 measure: Qualitative assessment of patient experience 2 measure: Qualitative assessment of patient experience 3 measure: Description of interactions between carers and patients measure: Comparison of the evolution and frequency of terms used by patients in the 2 groups during their care. measure: Studying the use of the 3D-printed kidney model introduced during the medical information consultation up to the post-operative visit by describing the life of the model throughout the entire care process measure: To study the level of understanding of renal anatomy and surgical issues according to the type of tool (personalized vs generic 3D printed model) measure: Comparison of the level of health literacy between the two groups at different times with changes in the average score on the literacy questionnaire (HLSEU-Q16: European Health Literacy Survey Questionnaire) measure: Description of the changes perceived by carers in patients management in both group sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU de Bordeaux city: Bordeaux country: France name: Gaëlle MARGUE, Docteur role: CONTACT lat: 44.84044 lon: -0.5805 hasResults: False
nctId: NCT06379685 id: SOPH190-0923/I briefTitle: Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. overallStatus: NOT_YET_RECRUITING date: 2024-09-30 date: 2025-04-30 date: 2025-04-30 date: 2024-04-23 date: 2024-04-23 name: Laboratorios Sophia S.A de C.V. class: INDUSTRY briefSummary: This is a phase I clinical study to evaluate the safety and tolerability of PRO-190 ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in ocular surface integrity, changes in the ocular comfort index (OCI) score, and IOP measurement compared to Systane Ultra®. conditions: Dry Eye conditions: Dry Eyes Chronic conditions: Dry Eye Syndromes studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Phase I, controlled, comparative, controlled, comparative. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Single-blind whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 32 type: ESTIMATED name: PRO-190 name: Systane Ultra® measure: Incidence Unexpected Related Adverse Reactions measure: Changes in the ocular comfort index (OCI) score in between interventions measure: Changes in Best Corrected Visual Acuity (BCVA) measure: Changes in tear film breakup time measure: Changes in intraocular pressure (IOP) measure: Changes in the integrity of the ocular surface (fluorescein staining) measure: Changes in lissamine green staining sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06379672 id: 2023[No.193] briefTitle: Resonance Breathing Training for Long Covid-related Myocardial Injury overallStatus: NOT_YET_RECRUITING date: 2024-05-25 date: 2024-08-25 date: 2024-09-05 date: 2024-04-23 date: 2024-04-23 name: Chengdu Sport University class: OTHER briefSummary: An investigation of the efficacy of resonance breathing training in the rehabilitation of patients with Long covid-related myocardial injury conditions: Long COVID conditions: Myocardial Injury studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 70 type: ESTIMATED name: Resonance breathing measure: New YorkHeart Association (NYHA) measure: left ventricle global longitudinal strain, LVGLS measure: hypertension measure: Average heart rate sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06379659 id: IR.MUI.MED.REC.1402.449 id: IRCT20110908007513N18 type: REGISTRY domain: IRAN registry of clinical trials (IRCT) briefTitle: Effectiveness of Intrauterine Growth Hormone Administration as an add-on Therapy to Conventional Hormone Therapy Compared to Placebo in Patients With Thin Endometrium Undergoing Frozen Thawed Embryo Transfer overallStatus: RECRUITING date: 2024-05 date: 2024-07 date: 2024-11 date: 2024-04-23 date: 2024-04-29 name: Isfahan University of Medical Sciences class: OTHER briefSummary: The purpose of this clinical trial is to see if intrauterine growth hormone infusions can help subjects reach a suitable endometrial thickness in patients who are resistant to routine hormonal therapy for embryo transfer in the In Vitro Fertilization (IVF) cycle.
The primary aim of this study is to assess the effectiveness of injecting Growth hormone directly into the uterus to enhance endometrial thickness. Additionally, we aim to compare the likelihood of pregnancy between patients receiving the Growth hormone infusion and those receiving a placebo. conditions: Thin Endometrium conditions: Infertility Female conditions: Infertility studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study was designed as a randomized controlled exploratory clinical trial, controlled with a parallel placebo group and random allocation using an online based system. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: In this study, a double-blind methodology will be employed to minimize bias. Patients will be administered medication without knowing the study group and placebo or treatment intervention. To ensure uniformity between growth hormone and placebo, which has a similar appearance to the placebo, will be prepared by an individual informed of the enrolled patients in the study and will be provided to the administering physician. The evaluator assessing outcomes such as clinical pregnancy rate and endometrial thickness will not know which treatment each patient received. Laboratory staff will also be unaware of the treatment groups. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 54 type: ESTIMATED name: Growh hormone name: Placebo measure: Endometrial thickness measure: Clinical Pregnancy Rate measure: Response to treatment measure: Implantation rate measure: IVF cancellation rate measure: Early pregnancy complications sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Isfahan Shahid Beheshti hospital, Hazrat e Maryam Fertility Center status: RECRUITING city: Isfahan zip: 8174673461 country: Iran, Islamic Republic of name: Nastaran Zamani Dehkordi role: CONTACT phoneExt: +989133842958 email: nastaran14zd@gmail.com name: Hatav Ghasemi Dehkordi role: CONTACT phoneExt: +989131134081 email: hatav.tehrani2014@gmail.com name: Hatav Ghasemi Tehrani role: PRINCIPAL_INVESTIGATOR lat: 32.65246 lon: 51.67462 hasResults: False
nctId: NCT06379646 id: YTS109-003 briefTitle: An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2025-04-21 date: 2026-04-21 date: 2024-04-23 date: 2024-04-23 name: China Immunotech (Beijing) Biotechnology Co., Ltd. class: INDUSTRY name: Shanghai Changzheng Hospital briefSummary: An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease conditions: Systemic Lupus Erythematosus conditions: Systemic Sclerosis conditions: Inflammatory Myopathy conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis conditions: Antiphospholipid Syndrome conditions: Sjogren's Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 6 type: ESTIMATED name: YTS109 measure: Safety outcomes measure: Efficacy outcomes for SLE measure: Efficacy outcomes for Sjogren's Syndrome measure: Efficacy outcomes for Systemic Sclerosis measure: Efficacy outcomes for Inflammatory Myopathy measure: Efficacy outcomes for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis measure: Efficacy outcomes for Antiphospholipid Syndrome measure: Peak Plasma Concentration (Cmax) of YTS109 measure: Time to Peak (Tmax) of YTS109 measure: Area under the plasma concentration versus time curve (AUC) of YTS109 measure: PD parameters sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06379633 id: s67010 briefTitle: Virtual Reality Exposure for Socially Anxious Adolescents acronym: VIRTUS overallStatus: RECRUITING date: 2024-03-27 date: 2026-06 date: 2026-06 date: 2024-04-23 date: 2024-04-23 name: KU Leuven class: OTHER name: Utrecht University briefSummary: Overall in this project, the primary goal is to evaluate the efficacy of virtual reality exposure (VRE) for adolescents with elevated social anxiety using a three-arm randomized controlled trial: (1) virtual reality exposure (VRE); (2) in vivo exposure (IVE); and (3) waitlist (WL) - the control condition.
It is predicted that both VRE and IVE will be more successful in decreasing social anxiety symptoms than the WL condition at post-assessment and that VRE will be as effective as in vivo in reducing social anxiety symptoms. Furthermore, it is expected that there will be no difference between the two active conditions in the long term (at 3- months \& 6-months follow up). Similar results are expected in the secondary outcome measures, intended to capture the participants' general well-being.